
Stefan Hinz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8705293/publications.pdf Version: 2024-02-01



STEEAN HINZ

#	Article	IF	CITATIONS
1	Porcupine Inhibition Disrupts Mitochondrial Function and Homeostasis in WNT Ligand–Addicted Pancreatic Cancer. Molecular Cancer Therapeutics, 2022, 21, 936-947.	1.9	4
2	Protocol for computationally evaluating the loss of stoichiometry and coordinated expression of proteins. STAR Protocols, 2022, 3, 101182.	0.5	0
3	Breast-Specific Molecular Clocks Comprised of <i>ELF5</i> Expression and Promoter Methylation Identify Individuals Susceptible to Cancer Initiation. Cancer Prevention Research, 2021, 14, 779-794.	0.7	11
4	Deep proteome profiling of human mammary epithelia at lineage and age resolution. IScience, 2021, 24, 103026.	1.9	3
5	Hijacking EMT: Better Fat Than Dead. Cancer Cell, 2019, 35, 1-2.	7.7	22
6	Inhibition of Discoidin Domain Receptor 1 Reduces Collagen-mediated Tumorigenicity in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2017, 16, 2473-2485.	1.9	86
7	Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer. Cancer Letters, 2015, 358, 59-66.	3.2	48
8	Enhancement of Nab-Paclitaxel Antitumor Activity through Addition of Multitargeting Antiangiogenic Agents in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2014, 13, 1032-1043.	1.9	19
9	Abstract B30: Selective small molecule AXL inhibitor BCB324 overcomes acquired drug resistance in non-small cell lung carcinoma models Clinical Cancer Research, 2014, 20, B30-B30.	3.2	3
10	Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies. Cancer Research, 2014, 74, 1747-1747.	0.4	11
11	Abstract 1025: Antitumor activity of nintedanib (BIBF 1120), a triple angiokinase inhibitor, in combination with gemcitabine in experimental pancreatic cancer. , 2014, , .		0
12	Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. Journal of Experimental and Clinical Cancer Research, 2013, 32, 12.	3.5	27
13	Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis, 2013, 34, 2361-2369.	1.3	107
14	PG545, an Angiogenesis and Heparanase Inhibitor, Reduces Primary Tumor Growth and Metastasis in Experimental Pancreatic Cancer. Molecular Cancer Therapeutics, 2013, 12, 1190-1201.	1.9	63
15	Superior Antitumor Activity of Nanoparticle Albumin-Bound Paclitaxel in Experimental Gastric Cancer. PLoS ONE, 2013, 8, e58037.	1.1	25
16	Abstract 2071: Addition of antiangiogenic agents enhances nab-paclitaxel antitumor activity in experimental pancreatic cancer , 2013, , .		0
17	Deep Proteome Profiling of Human Mammary Epithelia at Lineage and Age Resolution. SSRN Electronic Journal, 0, , .	0.4	0